For research use only
| Cat No. | ABC-TC475S |
| Product Type | Human Lymphoma Cell Lines |
| Cell Type | Lymphoblast |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | KARPAS-422; Karpas 422; KARPAS 422; Karpas422; KARPAS422; K422 |
KARPAS-422 B-cell NHL line from chemo-resistant lymphoma expresses CD19, CD37, IgM/IgG, grows in suspension, valuable for lymphoma biology and therapy.
KARPAS-422 is a human B-cell non-Hodgkin’s lymphoma (NHL) cell line established from the pleural effusion of a chemotherapy-resistant lymphoma of a 73 years old female patient. These cells exhibit large, round morphology with basophilic cytoplasm and are classified under the germinal center B-cell-like (GCB) subtype. KARPAS-422 harbors the hallmark t(14;18)(q32;q21) chromosomal translocation, leading to BCL2 overexpression, a key driver in lymphomagenesis. The cell line carries wild-type TP53 but demonstrates sensitivity to BCL2 inhibition, making it a preferred model for studying apoptosis and targeted therapy. KARPAS-422 expresses high levels of CD19, CD37, surface immunoglobulins (predominantly IgM and IgG), and CDw52 (CAMPATH-1). KARPAS-422 is tumorigenic in immunodeficient mice and is frequently used in preclinical models investigating epigenetic modulators, HDAC inhibitors, and BCL2-targeting agents.
| Product Code | KARPAS-422; Karpas 422; KARPAS 422; Karpas422; KARPAS422; K422 |
| Species | Human |
| Cat.No | ABC-TC475S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
KARPAS-422 can be used to explore the mechanism of Cyclin D1-dependent cell cycle dysregulation and the role of abnormal BCR (B cell receptor) signaling pathway in lymphoma progression. In addition, this cell line is also widely used to evaluate the efficacy of BTK inhibitors (such as ibrutinib), BCL-2 inhibitors (such as venetoclax) and proteasome inhibitors, helping to develop new targeted therapies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
